TABLE 3.
Antibacterial effect of pepducins and diagnostic routine antibiotics against clinical isolates
| Bacterial species (isolate no.) | Growth inhibition by pepducins (zone diam in mm)a |
Susceptibility pattern of antibiotics in the diagnostic routine panel (disc diffusion assay)b |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F2Pal12 | F2Myr12 | F2Pal16 | CAZ | MEM | TM | SXT | CIP | CO | AK | ATM | TZP | CTX | AM | VA | |
| Pseudomonas aeruginosa (1) | 5.2 ± 0.7 | 6.7 ± 0.7 | 8.0 ± 0.6 | S | I | R | R | R | S | R | I | S | R | ||
| P. aeruginosa (2) | 9.8 ± 0.5 | 13.3 ± 1.3 | 12.1 ± 0.1 | S | S | S | R | S | S | S | I | S | R | ||
| P. aeruginosa mucoid (3) | 8.3 ± 0.8 | 13.5 ± 0.3 | 9.4 ± 0.9 | S | S | S | R | S | S | S | I | S | R | ||
| P. aeruginosa mucoid (4) | 8.8 ± 0.6 | 12.3 ± 1.7 | 10.8 ± 0.8 | S | S | S | R | S | S | S | I | S | R | ||
| P. aeruginosa mucoid (5) | 7.8 ± 0.5 | 13.5 ± 0.9 | 10.8 ± 0.5 | S | S | S | R | S | S | S | I | S | R | ||
| Enterococcus faecalis (6) | 0 | 0 | 8.3 ± 1.3 | S | R | S | S | ||||||||
| E. faecalis (7) | 2.3 ± 1.2 | 2.0 ± 1.0 | 8.3 ± 0.9 | S | R | S | S | ||||||||
| E. faecalis (8) | 3.3 ± 1.8 | 2.3 ± 1.2 | 9.2 ± 0.8 | S | R | S | S | ||||||||
a
Zone sizes (mm) induced by pepducins (3 μl, 6 nmol) after subtracting the well diameter (3 mm) are given (mean ± SEM, n = 3 experiments).
b
S, susceptible; I, intermediate; R, resistant; CAZ, ceftazidime; MEM, meropenem; TM, tobramycin; SXT, trimethoprim-sulfamethoxazole; CIP, ciprofloxacin; CO, colistin; AK, amikacin; ATM, aztreonam; TZP, piperacillin-tazobactam; CTX, cefotaxime; AM, ampicillin; VA, vancomycin.